| Georgina H. Kilfoil |
Georgina H. Kilfoil is currently the Vice President-Clinical Operations at ATAI Life Sciences NV since 2020. She previously worked as the Vice President-Alliances & Project Management at Peninsula Pharmaceuticals, Inc. from 2004 to 2005, and as the SVP-Product Development & Project Management at Anthera Pharmaceuticals, Inc. from 2010 to 2013. From 2015 to 2019, she served as the Chief Development Officer at Benitec Biopharma Ltd. Kilfoil completed her undergraduate degree at the University of Bristol and earned an MBA from the Australian Graduate School of Management. |
| Florian Brand |
Florian Brand is the CEO and founder of ATAI Life Sciences AG and ATAI Life Sciences NV, both founded in 2018. He is currently a director at DemeRx, Inc., Innoplexus AG, Perception Neuroscience, Inc., COMPASS Pathfinder Holdings Ltd., GABA Therapeutics, Inc., EntheogeniX Biosciences, Inc., and Recognify Life Sciences, Inc. Mr. Brand was previously the CEO of Perception Neuroscience, Inc. from 2018 to 2019, the Managing Director of Springlane GmbH from 2015 to 2018, and a Non-Executive Director at Compass Pathways Plc from 2020 to 2021. Mr. Brand received his undergraduate degree from Ludwig-Maximilians-Universität München and his graduate degree from ESCP Europe Campus London. Brand is also the founder of EmpathBio, Inc., IntroSpect Digital Therapeutics, Inc., and Viridia Life Sciences, Inc. |
| Kevin Craig |
Kevin Craig is currently working as Vice President-Clinical Development at ATAI Life Sciences NV since 2021. Prior to this, he worked as Senior Director-Neuroscience at Labcorp Drug Development, Inc. and as Head-Early Clinical Development at Jazz Pharmaceuticals, Inc. Dr. Craig has a graduate degree from the University of Cambridge and the University of the Witwatersrand. |
| Samantha Bender |
Samantha Bender is currently working as a Senior Project Manager-Research & Development at ATAI Life Sciences NV since 2021. Prior to this, she worked as a Senior Program Manager at Agios Pharmaceuticals, Inc. Ms. Bender completed her undergraduate and graduate degrees from Northeastern University. |
| Michael Raven |
Michael Raven is currently the Vice President-Operations at ATAI Life Sciences NV since 2022. Previously, he worked at Bayer Pharmaceuticals as the Chief of Staff, Head-Communications & Strategy. He completed his undergraduate degree at WHU-Otto Beisheim School of Management. |
| Anne Johnson |
Anne Johnson is currently the Chief Financial & Accounting Officer at ATAI Life Sciences NV. She previously worked as the Corporate Controller at Chimerix, Inc., Vice President-Finance at Xanodyne Pharmaceuticals, Inc., and Controller at Aruvant Sciences, Inc. Ms. Johnson completed her undergraduate degree at The University of North Carolina at Wilmington. |
| Chris Lee |
Chris Lee is currently working as the Director of Information Technology at ATAI Life Sciences NV since 2021. Prior to this, he worked as the Director of Information Technology Operations at the American Academy of Orthopaedic Surgeons and as the Director of Information Technology & Infrastructure at PharMEDium Services LLC. Mr. Lee completed his undergraduate degree from Lewis University. |
| Srinivas G. Rao |
Srinivas G. Rao was the founder of Kyalin Biosciences, Inc. (founded in 2011) where he served as the Chief Executive Officer from 2011 to 2013. He is also the founder of ATAI Life Sciences AG (founded in 2018) where he currently holds the position of Chief Scientific Officer. Additionally, he is the founder of Kures, Inc. (founded in 2019) and ATAI Life Sciences NV (founded in 2018), both of which he currently serves as the Chief Scientific Officer. Dr. Rao is also the founder of IntroSpect Digital Therapeutics, Inc. Dr. Rao's current job(s) include being the Chief Executive Officer at EntheogeniX Biosciences, Inc. since 2019, a Director at Perception Neuroscience, Inc., a Member of the Society For Neuroscience, and a Member of the American College of Neuropsychopharmacology. Dr. Rao's former job(s) include being the Chief Scientific Officer & Director-Science at Cypress Bioscience, Inc. from 2000 to 2009, a Non-Executive Director at Bionomics Ltd. from 2020 to 2021, a Director at IntelGenx Technologies Corp. from 2021 to 2023, the Chief Medical Officer & Senior Vice President at Assertio Therapeutics, Inc. from 2014 to 2017, the Executive VP & Head-Neuroscience Division at Travere Therapeutics, Inc. from 2013 to 2014, and the Chief Medical Officer at Axial Therapeutics, Inc. from 2017 to 2019. Dr. Rao's education includes a doctorate from Yale School of Medicine and a doctorate from Yale Graduate School of Arts & Sciences. |
| Christian Angermayer |
Christian Angermayer founded Alnylam Europe AG in 2000, ATAI Life Sciences AG in 2018, Presight Capital in 2018, and various other companies. Mr. Angermayer also founded Apeiron Investment Group AG, Samara Asset Group Plc, North American Council For Online Learning Ltd., and various other companies. Mr. Angermayer also currently works at Frontier Acquisition Corp., as Chief Executive & Director, Blackrock Microsystems, Inc., as Director, London School of Hygiene & Tropical Medicine, as Court Member, and various other companies. Mr. Angermayer also formerly worked at Deutsche Maklerservice AG, as Director-Supervisory Board from 2004 to 2007, C-QUADRAT Investment AG, as Director-Supervisory Board from 2006 to 2008, VCH Investment Group AG, as Director-Management Board from 2005 to 2006, and various other companies. Mr. Angermayer received his undergraduate degree from the University of Bayreuth. |
| Sahil Kirpekar |
Sahil Kirpekar is currently working as a Director at IntelGenx Technologies Corp., Head-Business Development at Otsuka Pharmaceutical Co., Ltd., and Chief Business Officer at ATAI Life Sciences NV. He is a graduate of the University of Cambridge. |
| Frank Stegert |
Frank Stegert is the founder of 99chairs GmbH, which was founded in 2014. He is currently working as VP-Investment Management & Operations at ATAI Life Sciences AG since 2021, and also holds the position of Vice President-Investment Management at ATAI Life Sciences NV. He previously worked as Director at IntelGenx Technologies Corp. from 2021 to 2023, and as Senior Vice President & Head-Fund Banking at Deutsche Handelsbank AG from 2019 to 2020. Mr. Stegert completed his undergraduate degree from Technische Universität München. |
| Arvind Tewari |
Arvind Tewari is currently working as an Investment Manager at Epiris Managers LLP since 2016 and as a Vice President-Digital Strategy & Operations at ATAI Life Sciences NV since 2021. Previously, he worked as a Director at Sentinel Performance Solutions Group Ltd. from 2016 to 2019 and as a Chief Executive & Operating Officer at Oxford VR Ltd. He completed his undergraduate and graduate degrees from the University of Oxford. |
| Rolando GutÃerrez-Esteinou |
Presently, Rolando GutÃerrez-Esteinou occupies the position of Chief Medical Officer at ATAI Life Sciences NV.
He previously occupied the position of Senior Vice President-Medical & Pharmacovigilance at Aptinyx, Inc., VP-Clinical Development & Pharmacovigilance at Marinus Pharmaceuticals, Inc., Executive Director & VP-Global Therapeutic at Takeda Pharmaceutical Co., Ltd. and Vice President-Global Therapeutic Area at Labcorp Clinical Development GmbH.
He received a doctorate from Universidad Nacional Autónoma de México. |
